eRAM
encyclopedia of Rare Disease Annotation for Precision Medicine
| Disease | subependymal giant cell astrocytoma |
| Comorbidity | C0041341|tuberous sclerosis |
| Sentences | 44 |
| PubMedID- 24708766 | The rapamycin analogs cci-779 (temsirolimus) and rad001 (everolimus) are approved for the clinical treatment of advanced renal cell carcinoma [28], progressive neuroendocrine tumors of pancreatic origin [29], subependymal giant cell astrocytoma associated with tuberous sclerosis [30], and more recently for postmenopausal women with advanced hormone receptor-positive, her2-negative breast cancer in combination with the aromatase inhibitor exemestane [31]. |
| PubMedID- 23325902 | Objective: to report long-term efficacy and safety data for everolimus for the treatment of subependymal giant cell astrocytoma (sega) in patients with tuberous sclerosis complex (tsc). |
| PubMedID- 23548133 | Down-regulation of mtor kinase by everolimus has been successfully used for the therapy of subependymal giant-cell astrocytomas in patients with tuberous sclerosis. |
| PubMedID- 23231513 | Everolimus (rad001): first systemic treatment for subependymal giant cell astrocytoma associated with tuberous sclerosis complex. |
| PubMedID- 20133820 | Novel proteins regulated by mtor in subependymal giant cell astrocytomas of patients with tuberous sclerosis complex and new therapeutic implications. |
| PubMedID- 25669077 | [a case of tuberous sclerosis complicated by unusually located subependymal giant-cell astrocytoma]. |
| PubMedID- 24105488 | subependymal giant cell astrocytomas in patients with tuberous sclerosis complex: considerations for surgical or pharmacotherapeutic intervention. |
| PubMedID- 23138436 | The authors describe a rare case of subependymal giant cell astrocytoma (sega) associated with tuberous sclerosis complex that presented with intratumoral bleeding with extension to the ventricles. |
| PubMedID- 25557360 | Background: the aim of the study was to investigate factors affecting response to everolimus, a mammalian-target-of-rapamycin (mtor) inhibitor, of subependymal giant cell astrocytomas (sega) in patients with tuberous sclerosis complex (tsc). |
| PubMedID- 22136276 | Everolimus: in patients with subependymal giant cell astrocytoma associated with tuberous sclerosis complex. |
| PubMedID- 24756805 | Everolimus has been approved by the fda and the ema for the treatment of advanced renal cell carcinoma (rcc), subependymal giant cell astrocytoma (sega) associated with tuberous sclerosis (tsc), pancreatic neuroendocrine tumors (pnet), in combination with exemestane in advanced hormone-receptor (hr)-positive, her2-negative breast cancer. |
| PubMedID- 25227171 | Congenital subependymal giant cell astrocytomas in patients with tuberous sclerosis complex. |
| PubMedID- 23391693 | Management of subependymal giant cell astrocytoma (sega) associated with tuberous sclerosis complex (tsc): clinical recommendations. |
| PubMedID- 22805244 | Everolimus for tumor recurrence after surgical resection for subependymal giant cell astrocytoma associated with tuberous sclerosis complex. |
| PubMedID- 23743818 | Recent studies support the use of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis and suggest it might represent a disease-modifying treatment for other aspects of tuberous sclerosis. |
| PubMedID- 24757527 | Everolimus is effective in the treatment of large angiomiolypomas (aml) in patients with subependymal giant cell astrocytoma (sega) associated with tuberous sclerosis complex (tsc). |
| PubMedID- 22234227 | Hemorrhagic subependymal giant cell astrocytoma in a patient with tuberous sclerosis: case report and review of the literature. |
| PubMedID- 26381530 | Objective: to analyze the cumulative efficacy and safety of everolimus in treating subependymal giant cell astrocytomas (sega) associated with tuberous sclerosis complex (tsc) from an open-label phase ii study (nct00411619). |
| PubMedID- 21792104 | Mtor inhibitors in the treatment of subependymal giant-cell astrocytomas associated with tuberous sclerosis. |
| PubMedID- PMC3518234 | Down-regulation of mtor kinase by everolimus has been successfully used for the therapy of subependymal giant-cell astrocytomas in patients with tuberous sclerosis. |
| PubMedID- 22876836 | Outcomes of resecting subependymal giant cell astrocytoma (sega) among patients with sega-related tuberous sclerosis complex: a national claims database analysis. |
| PubMedID- 24667738 | This analysis focuses on the clinical presentation, management, and associated burden of subependymal giant cell astrocytomas in patients with tuberous sclerosis complex in the united states. |
| PubMedID- 20887114 | Rapamycin as an alternative to surgical treatment of subependymal giant cell astrocytomas in a patient with tuberous sclerosis complex. |
| PubMedID- 26137524 | Everolimus has since also been fda-approved for neuroendocrine tumors of pancreatic origin (pnet), breast carcinoma, and subependymal giant cell astrocytomas (sega) associated with tuberous sclerosis. |
| PubMedID- 23404211 | It is approved for the treatment of patients with progressive neuroendocrine tumors of pancreatic origin, advanced renal cell carcinoma, and subependymal giant cell astrocytoma associated with tuberous sclerosis [12]. |
| PubMedID- 23686401 | Everolimus is a mammalian target of rapamycin (mtor) inhibitor approved for the treatment of advanced renal cell carcinoma, pancreatic neuroendocrine tumors, subependymal giant cell astrocytoma associated with tuberous sclerosis complex, renal angiomyolipoma and tuberous sclerosis complex, and, in combination with exemestane, for hormone receptor-positive her2-negative advanced breast cancer after failure of treatment with letrozole or anastrozole. |
| PubMedID- 23158522 | Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (exist-1): a multicentre, randomised, placebo-controlled phase 3 trial. |
| PubMedID- 25493579 | The pathogenic activation of mtorc1 leads to the development of subependymal giant cell astrocytomas in patients with tuberous sclerosis complex. |
| PubMedID- 24507694 | Surgical treatment of subependymal giant cell astrocytoma in tuberous sclerosis complex patients. |
| PubMedID- 25143481 | Everolimus treatment for an early infantile subependymal giant cell astrocytoma with tuberous sclerosis complex. |
| PubMedID- 21047224 | Background: neurosurgical resection is the standard treatment for subependymal giant-cell astrocytomas in patients with the tuberous sclerosis complex. |
| PubMedID- 20643042 | Objective: presentation of 8 patients with subependymal giant-cell astrocytomas (sgca) associated with tuberous sclerosis complex (tsc). |
| PubMedID- 21297924 | From the bench to the bedside: everolimus for subependymal giant cell astrocytomas in tuberous sclerosis complex, optic nerve regeneration, targeted cytotoxins for gliomas. |
| PubMedID- 24244540 | Everolimus has been approved for second-line therapy of patients with renal cell carcinoma after failure of treatment with sunitinib and for the treatment of papillary renal carcinoma, pancreatic neuroendocrine tumor, some types of breast cancer, and subependymal giant cell astrocytoma associated with tuberous sclerosis [24]–[28]. |
| PubMedID- 22562196 | This has led to the approval of everolimus for the treatment of sega in tuberous sclerosis patients who are not candidates for surgery. |
| PubMedID- 23567018 | Long-term effect of everolimus on epilepsy and growth in children under 3 years of age treated for subependymal giant cell astrocytoma associated with tuberous sclerosis complex. |
| PubMedID- 24056156 | Congenital segmental lymphedema in tuberous sclerosis complex with associated subependymal giant cell astrocytomas treated with mammalian target of rapamycin inhibitors. |
| PubMedID- 25682485 | Conclusion: everolimus is a promising pharmacological approach to treat clinically significant inoperable cardiac rhabdomyomas or subependymal giant cell astrocytoma associated with tuberous sclerosis complex during the neonatal period. |
| PubMedID- 20422196 | The diagnosis and treatment of subependymal giant cell astrocytoma combined with tuberous sclerosis. |
| PubMedID- 22375958 | Outcomes of resecting subependymal giant cell astrocytoma (sega) among patients with sega-related tuberous sclerosis complex: a national claims database analysis. |
| PubMedID- 23183057 | The outcome of surgical management of subependymal giant cell astrocytoma in tuberous sclerosis complex. |
| PubMedID- 24276039 | Background: brain subependymal giant cell astrocytomas (segas) in patients with tuberous sclerosis have been reported to respond to everolimus. |
| PubMedID- 24667713 | Everolimus has demonstrated substantial clinical benefit in randomized, controlled, phase iii studies leading to approval for the treatment of advanced renal cell carcinoma, advanced neuroendocrine tumors of pancreatic origin, renal angiomyolipoma and subependymal giant-cell astrocytoma associated with tuberous sclerosis complex, as well as advanced hormone-receptor-positive (hr(+)) and human epidermal growth factor receptor-2-negative advanced breast cancer. |
| PubMedID- 24192699 | Equally important avenues of molecular investigation might include inhibiting disease-causing pathways, such as the proposed use of rapamycin for subependymal giant cell astrocytomas in children with tuberous sclerosis;(83) upregulating affected proteins from homologous genes as in models of spinal muscular atrophy (84); or counteracting the downstream effects of a deficient protein, such as the proposed use of igf1 in children with duchenne’s dystrophy [for review, please see liew, 2012 (85)]. |
Page: 1